Drug treatment options for the 2019-new coronavirus (2019-nCoV).

By Hongzhou Lu. BioScience Trends, 2020

1,101 citations recorded by the source corpus.

As of January 22, 2020, a total of 571 cases of the 2019-new coronavirus (2019-nCoV) have been reported in 25 provinces (districts and cities) in China. At present, there is no vaccine or antiviral treatment for human and animal coronavirus, so that identifying the drug treatment options as soon as possible is critical for the response to the 2019-nCoV outbreak. Three general methods, which include existing broad-spectrum antiviral drugs using standard assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of new specific drugs based on the genome and biophysical understanding of individual coronaviruses, are used to discover the potential antiviral treatment of human pathogen coronavirus. Lopinavir /Ritonavir, Nucleoside analogues, Neuraminidase inhibitors, Remdesivir, peptide (EK1), abidol, RNA synthesis inhibitors (such as TDF, 3TC), anti-inflammatory drugs (such as hormones and other molecules), Chinese traditional medicine, such ShuFengJieDu Capsules and Lianhuaqingwen Capsule, could be the drug treatment options for 2019-nCoV. However, the efficacy and safety of these drugs for 2019- nCoV still need to be further confirmed by clinical experiments.

Subfields: Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/7faee8fc20ae78213467fd0fef79d461d4327fdc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Siddappa N. Byrareddy
2. Hussin A. Rothan

Citations in the corpus

• The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China (2020, neutral): “The authors estimated that the reproduction number (R0) for SARSCoV-2 is 2.2, meaning that every infected person can infect a mean of 2.2 people.”
• COVID-19 outbreak: Migration, effects on society, global environment and prevention (2020, neutral): “Since SARS-CoV-2 is an RNA virus, any vaccines, effective against other RNA viruses such as measles, polio, encephalitis B and influenza, could be the most promising alternatives (Lu, 2020; Liu et al., 2020) .”
• Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV (2020, result): “Hong Kong scholars found that, compared with ribavirin alone, patients treated with lopinavir/ritonavir and ribavirin had lower risk of acute respiratory distress syndrome (ARDS) or death caused by SARS-CoV [76,77].”
• An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov) (2020, neutral): “Under the scenario of adopting the strongest prevention and control strategy and improving the level of detection and treatment in China, the previously estimated basic reproduction number is no longer suitable for evaluating the epidemic trend in the near future.”
• COVID-19: what has been learned and to be learned about the novel coronavirus disease (2020, background): “For example, Shu Feng Jie Du capsules and Lian Hua Qing Wen capsules were found to be effective for COVID-19 treatment [86] .”
• Coronavirus disease 2019 (COVID-19): A literature review (2020, neutral): “potential drugs from existing antiviral agent have also been proposed [66, 67].”
• How artificial intelligence and machine learning can help healthcare systems respond to COVID-19 (2020, background): “Vaccines and therapeutics for COVID-19 will take some time to be developed and introduced (Lu 2020).”
• Effectiveness of convalescent plasma therapy in severe COVID-19 patients (2020, neutral): “Currently, there are no approved specific antiviral agents targeting the novel virus, while some drugs are still under investigation, including remdesivir and lopinavir/ ritonavir (4, 5).”
• The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak (2020, background): “Another report on January 24, 2020 estimated the cumulative in cidence in China to be 5502 cases [9].”
• The novel coronavirus outbreak in Wuhan, China (2020, neutral): “molecules), Traditional Chinese Medicine (TCM), such Shu Feng Jie Du Capsules and Lian Hua Qing Wen Capsule, are being used as treatment options for COVID-19, but their efficacy and safety of these drugs are yet to be clinically observed in treatments [9].”